Eli Lilly has partnered with Boston’s Ascidian to develop RNA exon‑editing therapies for inherited kidney diseases in a deal that could be worth up to $1.9 billion. The collaboration pairs Ascidian’s platform with Lilly’s Seaport genetic‑medicine hub.

NSF is removing instruments from the Ocean Observatories Initiative, ending key below‑surface measurements off the Pacific Northwest as El Niño approaches.

A new multi‑university preprint finds just 10–15 minutes of AI help can reduce persistence and independent problem‑solving. The finding complicates how schools and workplaces should use chatbots.

Updated CHORD trial numbers presented in Seoul suggest most children with otoferlin‑related deafness gained meaningful hearing after Otarmeni treatment. The therapy was FDA‑cleared in April.

Early trial data show amivantamab shrank—and in some patients erased—tumors in treatment‑resistant head and neck cancer, with results set for ASCO on Sunday. Investigators call the responses striking but preliminary.

Boston Children's says its internal ChatGPT platform helped diagnose more than 40 rare conditions while reclaiming roughly 60,000 staff hours.

Massachusetts is investing $25M to help MIT build a shared Quantum Systems Laboratory at Building 39, promising new research jobs and easier startup access.

Andreessen Horowitz’s Tech Week lands in Boston next week with hackathons, biotech panels and a Perkins‑led DisabilityTech summit. The citywide calendar spans Kendall Square to the Seaport.

Analog Devices is reportedly close to buying Empower Semiconductor for about $1.5 billion to add power-delivery tech for AI data centers.

Gradiant closed a Series E that values the Boston water-tech firm at about $2B and said it aims for an IPO in roughly 18 months as it scales into AI and semiconductor markets.

Boston Scientific paid $1.5 billion for a roughly 34% stake in MiRus and an option to acquire the SIEGEL TAVR business, a potential fast path back into balloon‑expandable valves. The move hinges on clinical and regulatory milestones.

A new Frontiers study finds a small uptick in lung cancer incidence after COVID‑19, especially among current and former smokers, and points to the enzyme TYMP as a likely mechanism.

Biogen will advance diranersen — an antisense tau drug given intrathecally — to late‑stage trials after a Phase 2 readout showed tau reduction and hints of slowed decline.